Memory and thinking problems in people with primary aldosteronism
Follows people with primary aldosteronism to see how their memory and thinking change.
Key facts
- Who runs it
- Xinjiang Medical University
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- The Association Between Primary Aldosteronism and Cognitive Dysfunction
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 31 Dec 2025
- Expected to end
- Dec 2031
- Type of study
- Observational
- Record updated
- 5 January 2026
Who can take part
The trial is looking for adults aged 40 or older with primary aldosteronism (PA), a hormone condition that raises blood pressure. It follows their memory and thinking for up to 5 years.
- Age
- 40 years and older
- Sex
- All sexes
- Disease stage
- Primary aldosteronism confirmed by blood tests, with a positive screening test and a confirmatory test.
- Biomarker or test result
- Blood tests must confirm primary aldosteronism.
- Main reasons for not taking part
- Serious problems with sight, hearing or movement that prevent memory and thinking tests
- Past major brain or nerve disease, such as stroke, Parkinson's disease, brain tumor or severe head injury
- Past major mental illness, intellectual disability, or current use of antipsychotic medicines
- High blood pressure caused by another condition than PA
- Not willing to take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- 1. Aged ≥ 40 years
- 2. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test)
- 3. Ability to understand and cooperate with comprehensive neuropsychological assessment
- 4. Voluntary participation and provision of written informed consent
Who cannot take part
- 1. Significant visual, hearing, or motor impairment that prevents completion of cognitive testing
- 2. History of major neurological disorders (e.g., stroke, Parkinson's disease, intracranial tumor, severe traumatic brain injury)
- 3. History of major psychiatric illness, intellectual disability, or current use of antipsychotic medications
- 4. Diagnosis of secondary hypertension other than PA
- 5. Unwillingness to participate by the patient or their legal representative
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational study is to learn about the prevalence, progression, and influencing factors of cognitive impairment in patients with primary aldosteronism (PA). The main questions it aims to answer are:
Read full original descriptionShow less
1. What is the prevalence of baseline cognitive impairment in PA patients and what factors are associated with it? 2. What is the incidence of cognitive progression in PA patients within 1 and 5 years of follow-up and what factors influence this progression? Participants who are already diagnosed with PA as part of their regular medical care will be invited to join this long-term study. They will complete regular cognitive tests, medical check-ups, and questionnaires for up to 5 years. Some participants will also have optional blood tests and brain scans to help researchers understand the causes behind any cognitive changes.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Association Between Primary Aldosteronism and Cognitive Dysfunction
- Plain-language title
- Memory and thinking problems in people with primary aldosteronismGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07304674, who can take part
- Record updated
- 5 January 2026